Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
Uruguay: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Uruguay: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Uruguay?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Uruguay Patent 30,762
Patent Title: SAL FUMARATO DE (ALFA S, BETA R)-6-BROMO-ALFA-[2(DIMETILAMINO) ETIL]-2-METOXI-ALFA-1-NAFTALENIL-BETA-FENIL-3-QUINOLINAETANOL
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.
When can LASTACAFT (alcaftadine) generic drug versions launch in Uruguay?
Generic name: alcaftadine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 02, 2027
Generic Entry Controlled by: Uruguay Patent 30,254
Patent Title: TRATAMIENTOS PARA LA ALERGIA OCULAR

See drug price trends for LASTACAFT.
The generic ingredient in LASTACAFT is alcaftadine. Additional details are available on the alcaftadine profile page.
When can TRADJENTA (linagliptin) generic drug versions launch in Uruguay?
Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Uruguay Patent 30,319
Patent Title: FORMULACIONES DE INHIBIDORES DE DPP IV

See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.
When can BRILINTA (ticagrelor) generic drug versions launch in Uruguay?
Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Uruguay Patent 30,551
Patent Title: COMPOSICIONES FARMACÉUTICAS CONTENIENDO {1S-[1A(ALFA),2 A(ALFA), 3B(BETA)(1S*,2R*),5 B(BETA)]}-3-7-{[2-3,4-DIFLUOROFENIL)CICLOPROPIL]AMINO}-5-(PROPILITIO-3H-1,2,3-TRIAZOLO [4,5-D] PIRIMIDIN-3-Y 1-5-(2-HIDROXIETOXI)CICLOPENTANO-1,2-DIOL

See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
